ArticleJournal of thoracic disease2023
Robotic chest wall resection for primary benign chest wall tumors and locally advanced lung cancer: an institutional case series and national report.
Article in Journal of thoracic disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 9 citations in OpenAlex.
- Robot-assisted thoracoscopic resection of a costal cartilage chondrosarcoma mimicking anterior mediastinal teratoma: a case report.General thoracic and cardiovascular surgery cases · 2026Article
- Current advances in extended resections for non-small cell lung cancer-a narrative review.Translational lung cancer research · 2026Review
- Robotic Thoracic Surgery: Current Landscape and Future Directions.Interdisciplinary cardiovascular and thoracic surgery · 2026Review
- Short- and long-term outcomes of chest wall resection and reconstruction for breast cancer.The Journal of thoracic and cardiovascular surgery · 2026Article
- Technical Innovations and Complex Cases in Robotic Surgery for Lung Cancer: A Narrative Review.Current oncology (Toronto, Ont.) · 2025Review
- Robotic-Assisted Muscle-Sparing Chest Wall Resection Without Thoracotomy: Tips and Benefits for Lung Cancer Patients With Chest Wall Invasion.Annals of thoracic surgery short reports · 2025Article
- Robotic lobectomy with en bloc chest wall resection and reconstruction: How I do it.JTCVS techniques · 2025Article
- National trends, safety, and effectiveness of minimally invasive concomitant chest wall resection for locally advanced lung cancer.JTCVS open · 2024Article
- Tackling complex thoracic surgical operations with robotic solutions: a narrative review.Journal of thoracic disease · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Limited data exists for robotic chest wall resection; we report institutional and national experience of robotic chest wall resection. Methods: In this comparative retrospective case series we describe patients who underwent robotic chest wall resection at our institution and enrich this case series with data from the National Cancer Database (NCDB). We describe our preoperative workup, operative technique, and postoperative care. Outcomes included conversion to open, length of stay, readmissions, and 30- and 90-day mortality. The results are descriptively reported and compared. Results: We describe 6 patients institutionally and 96 NCDB patients. At our institution 66.7% were males, median age was 70.0 (range, 39-91) years, and 50% were primary chest wall tumors. Median tumor size was 5.25 (range, 2.3-8.3) cm. Outcomes were as follows: no open conversions, median length of stay 3 (range, 1-6) days, no unplanned 30-day readmissions or 90-day mortality. In the NCDB, 55.2% were males with median age of 68.5 (range, 30-89) years. Median tumor size was 3.90 (range, 2.4-6.0) cm. NCDB outcomes were as follows: 18.8% open conversion, median length of stay 7 (range, 5-10) days, 3.1% unplanned 30-day readmission, and 8.3% 90-day mortality. Our institutional case series had 18.0 months median follow-up (range, 6-54 months) with no functional deficits. Median survival in NCDB was 49.6 months. Conclusions: Robotic chest wall resection is feasible and is performed nationally with acceptable short- and long-term outcomes. Our institutional experience reports our technique, resultant short hospital stay, and excellent functional outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.